Education
About Us
Working with TipRanks
Follow Us
Skye Bioscience, Inc. (SKYE)
NASDAQ:SKYE
SKYE Analyst Ratings
Moderate Buy
5 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SKYE Stock 12 Month Forecast
Average Price Target
$9.80
▲(1052.94% Upside)
| Highest Price Target$20.00 | Average Price Target$9.80 | Lowest Price Target$2.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$20
Buy
2252.94%
Upside
Reiterated
11/12/25
Promising Adjunct Potential of Skye Bioscience's Nimacimab Reinforces Buy RatingValuations and Risks. Our price target of $20/share is based on an equally weighted composite of: (a) $22/share, as a 20x multiple of taxed and diluted 2034 EPS of $5/share discounted back to and (b) an NPV discounted cash flow of $17/share, with a discount rate of 14% and growth rate of 2%. These assumptions are in-line with the expected P/E multiple and discount rates of an early developmental-stage biopharmaceutical company.
Oppenheimer
$10
Buy
1076.47%
Upside
Reiterated
11/12/25
Craig-Hallum
―
Hold
―
Reiterated
11/12/25
William Blair
―
Buy
―
Reiterated
11/11/25
Piper Sandler
$13
Buy
1429.41%
Upside
Reiterated
11/11/25
Cantor Fitzgerald
$14→$2
Hold
135.29%
Upside
Downgraded
10/06/25
Citizens JMP
$16→$4
Buy
370.59%
Upside
Reiterated
10/06/25
Evercore ISI
$10
Buy
1076.47%
Upside
Initiated
08/15/25
Scotiabank
$20
Buy
2252.94%
Upside
Reiterated
05/09/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$20
Buy
2252.94%
Upside
Reiterated
11/12/25
Promising Adjunct Potential of Skye Bioscience's Nimacimab Reinforces Buy RatingValuations and Risks. Our price target of $20/share is based on an equally weighted composite of: (a) $22/share, as a 20x multiple of taxed and diluted 2034 EPS of $5/share discounted back to and (b) an NPV discounted cash flow of $17/share, with a discount rate of 14% and growth rate of 2%. These assumptions are in-line with the expected P/E multiple and discount rates of an early developmental-stage biopharmaceutical company.
Oppenheimer
$10
Buy
1076.47%
Upside
Reiterated
11/12/25
Craig-Hallum
―
Hold
―
Reiterated
11/12/25
William Blair
―
Buy
―
Reiterated
11/11/25
Piper Sandler
$13
Buy
1429.41%
Upside
Reiterated
11/11/25
Cantor Fitzgerald
$14→$2
Hold
135.29%
Upside
Downgraded
10/06/25
Citizens JMP
$16→$4
Buy
370.59%
Upside
Reiterated
10/06/25
Evercore ISI
$10
Buy
1076.47%
Upside
Initiated
08/15/25
Scotiabank
$20
Buy
2252.94%
Upside
Reiterated
05/09/25
Best Analysts Covering Skye Bioscience
1 Month
xxx
Success Rate
4/8 ratings generated profit
Average Return
-2.67%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -2.67% per trade.
3 Months
xxx
Success Rate
2/8 ratings generated profit
Average Return
-3.08%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -3.08% per trade.
1 Year
2 Years
xxx
Success Rate
0/8 ratings generated profit
Average Return
-57.76%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -57.76% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SKYE Analyst Recommendation Trends
Rating
Jun 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
9
10
11
11
11
Buy
4
5
6
7
7
Hold
0
0
0
2
3
Sell
3
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
15
17
20
21
Each month's total comprises the sum of three months' worth of ratings.
SKYE Financial Forecast
SKYE Stock Forecast FAQ
What is SKYE’s average 12-month price target, according to analysts?
Based on analyst ratings, Skye Bioscience, Inc.’s 12-month average price target is 9.80.
What is SKYE’s upside potential, based on the analysts’ average price target?
Skye Bioscience, Inc. has 1052.94% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SKYE a Buy, Sell or Hold?
Skye Bioscience, Inc. has a consensus rating of Moderate Buy which is based on 5 buy ratings, 2 hold ratings and 0 sell ratings.
What is Skye Bioscience, Inc.’s price target?
The average price target for Skye Bioscience, Inc. is 9.80. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $2.00. The average price target represents 1052.94% Increase from the current price of $0.85.
The highest analyst price target is $20.00 ,the lowest forecast is $2.00. The average price target represents 1052.94% Increase from the current price of $0.85.
What do analysts say about Skye Bioscience, Inc.?
Skye Bioscience, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of SKYE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.